@article{ea6adde5e9ee43cebdf8d84be17a0091,
title = "The intestinal barrier, an arbitrator turned provocateur in IBD",
author = "Saurabh Mehandru and Colombel, \{Jean Frederic\}",
note = "Funding Information: J.-F.C. has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire and Takeda; consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix and Viela bio; and holds stock options in Intestinal Biotech Development. S.M. has received consulting fees from Genentech, GlaxoSmithKline and Takeda. S.M. and J.-F.C. have an unrestricted, investigator-initiated grant from Takeda to examine novel homing mechanisms to the gastrointestinal tract. Funding Information: The authors would like to acknowledge the support of Bachetta Foundation.",
year = "2021",
month = feb,
doi = "10.1038/s41575-020-00399-w",
language = "English",
volume = "18",
pages = "83--84",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Research",
number = "2",
}